# Small molecule discovery



### Small Molecule Discovery in Oncology and Beyond: Challenges and Opportunities


Anton Simeonov, Ph.D.

Scientific Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

> TRACO Lecture October 3, 2022



## Drug discovery steps




# Screening assays

### **Range of Screening Assays**


### Extent of reductionism

Phenotype (Image-based HCS, GFP, etc)



Pathway (Reporters, e.g., luciferase, βlactamase)






Protein (Enzyme readouts, interactions, etc)




## Robotics





## HTS assays

#### 149 Cancer Relevant Cell-Based HTS Assays from PubChem



Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, S. G., Simeonov, A. and Hall, M. D. Small Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of FDA-Approved Drugs Pharmacological Reviews, October 2017, 69 (4) 479-496

Installational Sciences

### Assay expense

Important Considerations for Choosing an Assay

#### Assay expense

- Cost per well
- Disposal cost(s)



### Instrumentation

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation




# Throughput

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well



### Miniaturization

#### **Assay Miniaturization Saves Time and Reagents**



Rational Conter for Advancing Turnistional Eckerces

# Multiplex

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well
- Ability to multiplex
  - Can the response be measured by a single parameter; is multiparametric output possible?
  - Increased data per sample
  - Can guide hit slection by differentiating selectivity among related targets
  - Can distinguish pathway inhibition from cytotoxicity in a cell-based assay



### Reagents

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well
- Ability to multiplex
  - Can the response be measured by a single parameter; is multiparametric output possible?
  - Increased data per sample
  - Can guide hit slection by differentiating selectivity among related targets
  - Can distinguish pathway inhibition from cytotoxicity in a cell-based assay
- Reagents
  - Stablility for hours is important
  - Consistency is critical (ideally obtain a large quantity from a single lot)
  - All reagents need to be validated (cell lines, antibodies, enzymatic purity, etc.)




## Interference

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well
- Ability to multiplex
  - Can the response be measured by a single parameter; is multiparametric output possible?
  - Increased data per sample
  - Can guide hit slection by differentiating selectivity among related targets
  - Can distinguish pathway inhibition from cytotoxicity in a cell-based assay
- Reagents
  - Stablility for hours is important
  - Consistency is critical (ideally obtain a large quantity from a single lot)
  - All reagents need to be validated (cell lines, antibodies, enzymatic purity, etc.)
- Potential for assay interference
  - Fluorescent compounds can interfere with fluorescent readouts
  - Colored compounds might interfere with luminescence



# Spectroscopic profiling

#### Fluorescence Spectroscopic Profiling of Compound Libraries




Simeonov, A., Jadhav, A., Thomas, C.J., Wang, Y., Huang, R., Southall, N.T., Shinn, P., Smith, J., Austin, C.P., Auld, D.S. and Inglese, J., 2008. Fluorescence spectroscopic profiling of compound libraries. *Journal of Medicinal Chemistry*, 51(8), 2363-2371.



## Tolerance to DMSO

#### **Determination of Assay Tolerance to DMSO/Vehicle is Important**



Yasgar A., Jadhav A., Simeonov A., Coussens N.P., AlphaScreen-Based Assays: Ultra-High-Throughput Screening for Small-Molecule Inhibitors of Challenging Enzymes and Protein-Protein Interactions. *Methods Mol Biol.* 2016;1439:77-98.



## Homogenous format

- Homogenous assay format is preferred for screening
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility



## Time required

- Homogenous assay format is preferred for screening
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility
- Time required for assay
  - Off-line reagent preparation
  - Is temperature equilibration required
  - Actual assay time
  - Kinetic versus end point read
  - Time required for data analysis and record keeping



# Signal stability

- Homogenous assay format is preferred for screening
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility
- Time required for assay
  - Off-line reagent preparation
  - Is temperature equilibration required
  - Actual assay time
  - Kinetic versus end point read
  - Time required for data analysis and record keeping
- Signal stability
  - Does the response occur rapidly or within a few minutes or hours?
  - Longer signal stability allows for flexibility in automated systems
  - Longer signal stability minimizes differences among plates within a stack



# Sensitivity

#### Important Considerations for Choosing an Assay


#### Homogenous assay format is preferred for screening

- Add reagents, mix and measure (no solution removal or wash steps)
- Automation friendly
- Reduces variability
- Decreases hands-on time
- Improves reproducibility
- Time required for assay
  - Off-line reagent preparation
  - Is temperature equilibration required
  - Actual assay time
  - Kinetic versus end point read
  - Time required for data analysis and record keeping
- Signal stability
  - Does the response occur rapidly or within a few minutes or hours?
  - Longer signal stability allows for flexibility in automated systems
  - Longer signal stability minimizes differences among stacks of plates
- Assay Sensitivity
  - Choice of readouts is important
    - Colorimetric<fluorescent<luminescent</li>




## **Evaluating assay**

#### **Evaluating Assay Suitability for Screening**



# Suitability

#### **Evaluating Assay Suitability for Screening**




A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Zhang JH, Chung TD, Oldenburg KR. J Biomol Screen. 1999;4(2):67-73.



## Quantitative HTS

### Improving the Process of Early Discovery: Quantitative High-Throughput Screening (qHTS)



PNAS 103:11473


- Conventional screening done at one concentration
  - Not appropriate for potency testing "dose makes the poison"
- qHTS tests compounds assayed at multiple concentrations (range: 4 logs)
- Enabled by miniaturized assay volumes (2-8 µL per test) and informatics pipeline

Generates pharmacological actives instead of statistical "hits"

- Dramatically increases reliability
- Dramatically reduces false positives and false negatives
- To date, several hundred million datapoints from several hundred screens have been generated and deposited in the public domain.


### Medicinal chemistry

### **Medicinal Chemistry, an Integrated Process**




### Drug combinations

#### Translation Challenge: Rapid Discovery of Drug Combinations



### Resistance

#### Application of Drug Combinations to Address Resistance







### Dissemination


### Dissemination of technology: combination screening to overcome drug resistance in cancer cells

- Applied to ABC subtype of Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
- Ibrutinib is a BTK inhibitor that has activity against ABC DLBCL
- Lead investigators: Craig Thomas (NCATS) and Louis Staudt (NCI)
- Study evaluated 459 drugs in combination with Ibrutinib
  - » 6 x 6 concentration-response "matrix blocks", validation in 10 x 10 concentration-response matrix blocks
- DNA-damaging agents identified as synergizing with Ibrutinib in killing ABC DLBCL cell lines
- Dissemination:
  - » Protocols
  - » Source code for dispense

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

Leeley A. Michevet Griner<sup>14</sup>, Rajanhi Guha<sup>14</sup>, Paul Shien<sup>14</sup>, Byan M. Young<sup>14</sup>, Jonathan M. Keller<sup>1</sup>, Dongbo Ua<sup>4</sup>, Ian S. Goldisti<sup>1</sup>, Adam Yanga<sup>14</sup>, Crystal McKnight<sup>1</sup>, Motthew B. Boxe<sup>14</sup>, Danien Y. Duveas<sup>1</sup>, Ran-Kang Jang<sup>1</sup>, Sam Michael<sup>17</sup>, Tim Mierzwei<sup>1</sup>, Wennau Huang<sup>1</sup>, Martin J. Walkh<sup>1</sup>, Bryan T. Mott<sup>1</sup>, Persena Pole<sup>11</sup>, William Leister<sup>1</sup>, Dovid J. Moloney<sup>1</sup>, Christopher A. Lecleir<sup>16</sup>, Gametha Ra<sup>2</sup>, Ajit Jadhu<sup>1</sup>, Brjan D. Pryser<sup>1</sup>, Oristopher P. Austin<sup>15</sup>, Soath E. Marite<sup>1</sup>, Anton Simaenev<sup>1</sup>, Marc Herner<sup>1</sup>, Louis M. Staud<sup>11</sup><sup>10</sup>, and Craig J. Therm<sup>12</sup>

"Bolazian of Pacifiesial Instances, National Institution of Naukh Ownikal Generation Context, National Genera for Advancing Disentational Non-Mathabilities Reach, Schefer for Concern Research, and "Researching approximation Arcogence, Solicit of Concern Treatment and Desparation, Reference Concern Treatment, Beakage Laternational Concern Treatment and Desparation, Reference Concern Treatment, Net Concern Research, Reference Concern Treatment, Net Concern Research, Reference Concern Concern Research, Reference Resear



PNAS 111, 2349-2354


framelational file


## Triple drug combination

#### Example: triple drug combination screening to tackle resistance against artemisinin-based combination therapies in malaria


ACS Pharmacol. Transl. Sci. 2020, https://dx.doi.org/10.1021/acsptsci.0c00110?ref=pdf









To each replicate block, serial dilutions of Drugs C is acoustically dispensed, with the final block serving as a DMSO control



③ Plate view of triple combination screening plate with positive control (artesunate, blue) and neutral controls (DMSO, grey) also shown.




- Dispense P. falciparum and erythrocytes, incubate 72 hr
- S Dispense 2 μL of SYBRGreen1 and lysis solution, incubate overnight. Fluorescence quantified



- (6) Parasite proliferation response is normalized to artesunate and DMSO controls. For each concentration Drug C block, response of Drug A + Drug B wells is summed.
- 3000 4 2000-0 1000--9 -8 -7 -6 -5 Drug C (Log [M])
  - Triple drug response is analyzed as a function of Drug C concentration.

### **VIPOR** combination




https://www.onclive.com/view/vipor-regimen-is-safe-showsimpressive-activity-in-relapsed-refractory-dlbcl https://www.targetedonc.com/view/vipor-regimensignals-benefit-in-patients-with-mantle-cell-lymphoma



H) Automatic Contar for Automating

### 3D models

### Increasing the predictivity of *in vitro* assays: a continuum of 3D models of healthy and diseased tissues









## **Tissue bioprinting**

### **3D Tissue Bioprinting**



## 3D tissue models

### **Current portfolio of engineered 3D tissue models**




Program Director Marc Ferrer, Ph.D. https://ncats.nih.gov/bioprinting



## Skin biofabrication


### **Skin biofabrication**





# Skin tissue generation

### Generation of bioprinted skin tissues



for Advancing

Z Wei and X Liu et al., Frontiers in Bioengineering and Biotechnology (2020)


# Tissue model

www.oncotarget.com

Oncotarget, 2020, Vol. 11, (No. 27), pp: 2587-2596

**Research Paper** 

A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue



Collaboration between NCATS (Marc Ferrer) and Rockefeller University (Daniel Gareau)




## Information

### Where do I go for more information about assay development?



## Book

# Sharing internal know-how: Assay Guidance Manual (47 chapters/ 1,338 printed pages)



Preface Table of Contents	
Considerations for Early Phase Drug Discovery	1 Chapter
In Vitro Biochemical Assays	10 Chapters
In Vitro Cell Based Assays	19 Chapters
In Vivo Assay Guidelines	2 Chapters
Assay Artifacts and Interferences	4 Chapters
Assay Validation, Operations and Quality Control	5 Chapters
Assay Technologies	2 Chapters
Instrumentation	2 Chapters
Pharmacokinetics and Drug Metabolism	1 Chapter
Glossary of Quantitative Biology Terms	1 Chapter

Website:https://ncats.nih.gov/expertise/preclinical/agm

17427244

#### Email us: NCATS AGM Editors@mail.nih.gov



#### https://ncats.nih.gov/agm-video

#### August 7th Videos

- 1. Austin, CP: Welcome to the Assay Guidance Manual (AGM) Workshop
- 2. Coussens, NP: Strategies for Assay Selection & Robust Biochemical Assays
- 3. Riss, T: Treating Cells as Reagents to Design Reproducible Screening Assays
- 4. Trask, OJ: Assay Development Considerations for High Content Imaging
- 5. Auld, DS: Studies in Mechanisms and Methods in Assay Interferences
- 6. Dahlin, JL: Assay Interference by Chemical Reactivity
- 7. Chung, TDY: Basic Assay Statistics, Data Analysis & Rules of Thumb
- 8. Devanarayan, V: Reproducibility & Differentiability of Potency Results
- 9. Sittampalam, GS: Avoiding Artifacts & Interferences in Assay Operations

#### March 26-27th Videos

- 1. Austin, CP: Welcome to the Assay Guidance Manual (AGM) Workshop
- 2. Coussens, NP: Robust Assays Define Success in Preclinical Research
- 3. Lal-Nag, M: Target Identification & Validation in Translational Discovery
- Foley, TL: Development & Validation of Cell-Based and Biochemical Assays
- 5. Riss, T: Treating Cells as Reagents to Design Reproducible Screening Assays
- Trask, OJ: Assay Development for HCS & Best Practices for 3D HCS
- 7. Roth, KD: Mass Spectrometry for Drug Screening and Lead Optimization
- 8. Dahlin, JL: Bioassay Interference by Aggregation and Chemical Reactivity
- 9. Patnaik, S: Lead Selection and Optimization by Medicinal Chemistry
- 10. Xia, M: In Vitro Toxicological Testing Using a qHTS Platform
- 11. Xu, X: In Vitro Assessment of ADME Properties of Lead Compounds
- 12. Kahl, SD: Statistical Design of Experiments for Assay Development
- 13. Guha, R: Pharos Application to Target Evaluation and Drug Discovery
- 14. Weidner, JR: Assay Operations: Keeping Assays Robust and Reproducible



# Assay guidance manual

#### Assay Guidance Manual Training Workshops



National Center for Advancing Translational Sciences

- Online Training Modules
- <u>Upcoming Workshops</u>
- Past Workshops

NCATS offers a variety of <u>Assay Guidance Manual (AGM</u>) training workshops throughout the year designed to share best practices and advice on robust assay design, development and implementation for researchers involved in the drug discovery process.



#### Online Training Modules

NCATS offers an online AGM training workshop in addition to the in-person AGM workshops held throughout the year. The online training workshop also features experts sharing best practices and expert advice on assay design, development and implementation. <u>View the video modules</u>.

#### Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development

Tue Jun 7, 11:00 AM - Wed Jun 8, 5:15 PM (EDT)
Zoom
Addts calendar \*
# Share \*

#### THIS EVENT HAS ENDED

Video of the workshop is available at the links below:

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 1) (June 7, 2022)

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 2) (June 8, 2022)

#### About the Workshop

The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) program is hosting a two-day workshop that will cover a broad range of critical concepts, including practical approaches and best practices, for developing standardized 3D cellular assays with the hope of helping the community to successfully develop therapeutics for future pandemic threats. This workshop is jointly organized by NCATS, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation. The overall goal of this workshop is to help scientists establish robust, reproducible, scalable, consistent, advanced 3D tissue models to study pandemic threat viruses.

### https://ncats.nih.gov/expertise/preclinical/agm/training



### WORKSHOP



BUILDING 35A • NIH MAIN CAMPUS • BETHESDA, MD



16 TALKS INCLUDING CASE STUDIES BY EXPERTS FROM GOVERNMENT, INDUSTRY AND ACADEMIA

Topics include: reproducibility, assay development, HTS data analysis, biophysical techniques, medicinal chemistry, DNA-encoded libraries and 3D tissue models for drug discovery



REGISTER AT https://ncats.corsizio.com/c/626855c6a72266e768c48416





### NCATS

